Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ761246B2 - Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF - Google Patents
[go: Go Back, main page]

NZ761246B2 - Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF - Google Patents

Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF Download PDF

Info

Publication number
NZ761246B2
NZ761246B2 NZ761246A NZ76124616A NZ761246B2 NZ 761246 B2 NZ761246 B2 NZ 761246B2 NZ 761246 A NZ761246 A NZ 761246A NZ 76124616 A NZ76124616 A NZ 76124616A NZ 761246 B2 NZ761246 B2 NZ 761246B2
Authority
NZ
New Zealand
Prior art keywords
vegf inhibitor
patient
vegf
macular degeneration
genetic variant
Prior art date
Application number
NZ761246A
Other versions
NZ761246A (en
Inventor
Sara Hamon
Charles Paulding
Lorah Perlee
Original Assignee
Regeneron Pharmaceuticals Inc
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority claimed from NZ744025A external-priority patent/NZ744025A/en
Publication of NZ761246A publication Critical patent/NZ761246A/en
Publication of NZ761246B2 publication Critical patent/NZ761246B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Disclosed herein are methods for associating a genetic variant with improved visual acuity in patients with wet macular degeneration who have previously been treated with a VEGF inhibitor for about one year, wherein the genetic variant is rs12148845 or rs12148100. Also disclosed is the treatment of these patients with a VEGF inhibitor in an amount of about 2mg quarterly.

Claims (11)

What is claimed is:
1. Use of a vascular elial growth factor (VEGF) tor in the cture of a medicament for the treatment of a wet macular degeneration patient, the patient having previously been treated with the VEGF inhibitor for about one year, the patient having one or more genetic variants determined by performing or having performed a genotype assay on a DNA sample obtained from the patient, wherein the one or more genetic variants are single nucleotide polymorphisms rs12148845 and 8100, and wherein the VEGF inhibitor is formulated for intravitreal administration to the patient in an amount of about 2 mg quarterly after the about one year previous treatment with the VEGF inhibitor.
2. The use of claim 1, wherein the single nucleotide polymorphism is rs12148845.
3. The use of claim 1, wherein the single nucleotide rphism is 8100.
4. The use of any one of claims 1 to 3, wherein the VEGF inhibitor is ranibizumab.
5. The use of any one of claims 1 to 3, wherein the VEGF inhibitor is aflibercept.
6. A method of associating a genetic variant with ed visual acuity in a wet macular degeneration patient having previously been treated with a VEGF inhibitor for about one year, the method comprising: performing a genotype assay on a DNA sample obtained from the patient to determine the presence or absence of the c variant associated with improved visual acuity, wherein the genetic variant is rs12148845 and rs12148100, wherein when the t has the genetic variant, the patient is a candidate for intravitreal administration with a VEGF inhibitor in an amount of about 2 mg quarterly.
7. The method of claim 6, wherein the genetic variant is rs12148845.
8. The method of claim 6, wherein the genetic variant is rs12148100.
9. The method of any one of claims 6 to 8, wherein the VEGF inhibitor is ranibizumab.
10. The method of any one of claims 6 to 8, wherein the VEGF inhibitor is aflibercept.
11. The method of any one of claims 6 to 10, n the improved visual acuity is a Gain of 15 letters. ”Hi/8 gm gmmgmnmanm m ?wmamé 3m ??w 3% ”mam”. 3mm a“ msmwamn? émmwm gamma: xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
NZ761246A 2016-12-01 Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF NZ761246B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262589P 2015-12-03 2015-12-03
US201662291274P 2016-02-04 2016-02-04
NZ744025A NZ744025A (en) 2015-12-03 2016-12-01 Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf

Publications (2)

Publication Number Publication Date
NZ761246A NZ761246A (en) 2024-10-25
NZ761246B2 true NZ761246B2 (en) 2025-01-28

Family

ID=

Similar Documents

Publication Publication Date Title
IL259672B2 (en) Methods for associating genetic variants with clinical outcome in patients suffering from age-related macular degeneration and receiving treatment against tubular endothelial growth factor
Njiokou et al. Domestic animals as potential reservoir hosts of Trypanosoma brucei gambiense in sleeping sickness foci in Cameroon
Panesso et al. Methicillin-susceptible, vancomycin-resistant Staphylococcus aureus, Brazil
JP2017511131A5 (en)
Saify et al. Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and heroin dependence
Park et al. Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients
Gan-Or et al. Genetic markers of restless legs syndrome in Parkinson disease
Le et al. Functional annotation of genetic loci associated with sepsis prioritizes immune and endothelial cell pathways
Khanaliha et al. Double-stranded RNA viral infection of Trichomonas vaginalis (TVV1) in Iranian isolates
Mohanty et al. Evolutionary interplay of single nucleotide polymorphisms at the promoter region of TNF-α gene in different clinical outcomes of malaria in India
Kuuliala et al. Polymorphism at position+ 896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis
NZ761246B2 (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
Thakur et al. Genetic diversity in the C-terminal 42 kDa region of merozoite surface protein-1 of Plasmodium vivax (PvMSP-142) among Indian isolates
NZ761242B2 (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
Di Fusco et al. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses
Лефтеров et al. Simulation and psychological trainings as methods of preventing emotional burnout in doctors
Zhao et al. Endothelial nitric oxide synthase 894 G> T polymorphism and thrombotic disease: A Meta-Analysis of 17 studies involving 8808 subjects
Hernández-Rivera et al. NRAMP1 polymorphisms like susceptibility marker in Mexican focus of cutaneous leishmaniasis
Gendrot et al. Modulation of in vitro antimalarial responses by polymorphisms in Plasmodium falciparum ABC transporters (pfmdr1 and pfmdr5)
Moron et al. Detection of azole resistance and ERG11 point mutations in Candida albicans isolates from tertiary hospitals in the Philippines
CN104726608B (en) Application method of VEGFR2 gene Val297Ile site
Samadzadeh et al. HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients
Dosunmu-Ogunbi et al. The role of SOD2 in maintaining endothelial cell function in SCD
Poovindran Anada et al. A prevalence study of single nucleotide polymorphisms in the promoter of the apolipoprotein E gene in different ethnic groups in Malaysia.
Hobbs et al. B37 TELL ME WHY: COPD PATHOGENESIS: Coding Variant Associations With Lung Function And COPD Using An Exome Array